Pharmaceutical Compounds
First Claim
Patent Images
1. A compound of formula I:
- wherein R1 and R2 are independently from each other hydrogen or a group which is hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl;
X represents a methylene group;
Y represents an atom of oxygen, nitrogen or sulphur;
n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1;
R3 represents a pyridine group according to the formula A, B or C, which is connected as indicated by the unmarked bond;
where R4, R5, R6 and R7 independently from each other represent hydrogen, C1-C6-alkyl, C1-C6-thioalkyl, C1-C6-alkoxy, C6-C12-aryloxy or a C6-C12-thioaryl group, C1-C6-alkanoyl or C7-C13-aroyl group, amino, C1-C6—
alkylamino, C1-C6-dialkylamino, C3-C12-cycloalkylamino, C3-C12-heterocycloalkylamino, C1-C6-alkylsulphonyl, C6-C12-arylsulphonyl, halogen, C1-C6-haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group;
or two or more of residues R4, R5, R6 and R7 taken together represent aliphatic or heteroaliphatic rings or aromatic or hetero aromatic rings and wherein P represents a central unit, which is preferably a planar unit and which is even more preferably selected from the regioisomers of 1,3,4-oxadiazol-2,5-diyl, 1,2,4-oxadiazol-3,5-diyl, 4-methyl-4H-1,2,4-triazol-3,5-diyl, 1,3,5-triazin-2,4-diyl, 1,2,4-triazin-3,5-diyl, 2H-tetrazol-2,5-diyl, 1,2,3-thiadiazol-4,5-diyl, 1-alkyl-3-(alkoxycarbonyl)-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl and wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, 1-alkyl-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl, thiazol-2,4-diyl, 1-H-pyrazol-1,5-diyl, pyrimidin-2,4-diyl, oxazol-2,4-diyl, carbonyl, 1H-imidazol-1,5-diyl, isoxazol-3,5-diyl, furan-2,4-diyl, 3-alkoxycarbonylfuran-2,4-diyl, wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, benzene-1,3-diyl and (Z)-1-cyanoethen-1,2-diyl;
or a pharmaceutically acceptable salt or ester of a compound of formula I.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.
59 Citations
50 Claims
-
1. A compound of formula I:
-
wherein R1 and R2 are independently from each other hydrogen or a group which is hydrolysable under physiological conditions, optionally substituted lower alkanoyl or aroyl;
X represents a methylene group;
Y represents an atom of oxygen, nitrogen or sulphur;
n represents the number 0, 1, 2 or 3 and m represents the number 0 or 1;
R3 represents a pyridine group according to the formula A, B or C, which is connected as indicated by the unmarked bond;where R4, R5, R6 and R7 independently from each other represent hydrogen, C1-C6-alkyl, C1-C6-thioalkyl, C1-C6-alkoxy, C6-C12-aryloxy or a C6-C12-thioaryl group, C1-C6-alkanoyl or C7-C13-aroyl group, amino, C1-C6—
alkylamino, C1-C6-dialkylamino, C3-C12-cycloalkylamino, C3-C12-heterocycloalkylamino, C1-C6-alkylsulphonyl, C6-C12-arylsulphonyl, halogen, C1-C6-haloalkyl, trifluoromethyl, cyano, nitro or a heteroaryl group;
or two or more of residues R4, R5, R6 and R7 taken together represent aliphatic or heteroaliphatic rings or aromatic or hetero aromatic rings and wherein P represents a central unit, which is preferably a planar unit and which is even more preferably selected from the regioisomers of 1,3,4-oxadiazol-2,5-diyl, 1,2,4-oxadiazol-3,5-diyl, 4-methyl-4H-1,2,4-triazol-3,5-diyl, 1,3,5-triazin-2,4-diyl, 1,2,4-triazin-3,5-diyl, 2H-tetrazol-2,5-diyl, 1,2,3-thiadiazol-4,5-diyl, 1-alkyl-3-(alkoxycarbonyl)-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl and wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, 1-alkyl-1H-pyrrol-2,5-diyl, wherein alkyl is represented by methyl, ethyl, n-propyl and n-butyl, thiazol-2,4-diyl, 1-H-pyrazol-1,5-diyl, pyrimidin-2,4-diyl, oxazol-2,4-diyl, carbonyl, 1H-imidazol-1,5-diyl, isoxazol-3,5-diyl, furan-2,4-diyl, 3-alkoxycarbonylfuran-2,4-diyl, wherein alkoxy is represented by methoxy, ethoxy, n-propoxy and isopropoxy, benzene-1,3-diyl and (Z)-1-cyanoethen-1,2-diyl;
or a pharmaceutically acceptable salt or ester of a compound of formula I.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
wherein R4, R5, R6 and R7 are defined as in the general formula I in claim 1, is subjected to cyclisation with a compound of formula III under conditions suitable to produce oxadiazole derivatives of formula VIA, VIB or VIC, optionally followed by removal of the protecting groups R8 and/or R9. -
26. Process according to claim 25, wherein the compound of formula III is activated by reaction with thionyl chloride or 1,1-carbonyldiimidazole.
-
27. Process according to claim 25 or 26, wherein the cyclisation step consisting of condensation and dehydration is conducted sequentially in a one-pot reaction.
-
28. Process according to any one of claims 25 to 27, wherein the cyclisation step is carried out in the presence of a suitable organic base.
-
29. Process according to claim 28, wherein the cyclisation step is carried out in the presence of pyridine.
-
30. Process according to any one of claims 25 to 29 wherein the groups R8 and R9 are independently from each other or jointly removed and replaced with hydrogen or a group which is hydrolysable under physiological conditions.
-
31. Process according to any one of claims 25 to 30 wherein R8 and R9 of the compound of formula III independently from each other represent methyl or hydrogen.
-
32. Process according to claim 31, wherein the methyl group is removed by reaction with aluminium chloride and pyridine in N-methylpyrrolidinone.
-
33. Process according to any one of claims 25 to 32, wherein the condensation and dehydration is performed in a dipolar aprotic solvent.
-
34. Process according to claim 33, wherein the condensation and dehydration is performed in dimethylacetamide, N-methylpyrrolidinone or dimethylsulfoxide.
-
35. Process according to any one of claims 25 to 34, wherein the compound of formula VA, VB or VC is obtained by the reaction of compound VIIIA, VIIIB or VIIIC, respectively,
wherein R4, R5, R4 and R7 are defined as in the general formula I in claim 1, with hydroxylamine in the presence of a chelating agent under conditions suitable to produce amidoxime derivatives. -
36. Process according to claim 35, wherein the chelating agent is selected from the group consisting of 8-hydroxyquinoline, ortho-phenanthroline and hydrates or derivatives thereof.
-
37. Use of a compound of formula I as defined in claim 1, or a pharmacologically acceptable salt or ester thereof, for the preparation of a medicament for administration according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day, for the prevention or treatment of central and peripheral nervous system associated disorders.
-
38. Use according to claim 37, wherein the dosing regimen is once daily.
-
39. Use according to claim 37, wherein the dosing regimen is once every other day.
-
40. Use according to any one of claims 37 to 39, wherein the central and peripheral nervous system associated disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.
-
41. Method as claimed in claim 40, wherein the movement disorder is restless leg syndrome, Parkinson'"'"'s disease or a pathological state involving Parkinsonism.
-
42. Use according to any one of claims 37 to 41, wherein the central and peripheral nervous system associated disorder is treatable by a L-DOPA/AADC therapy.
-
43. Use according to any one of claims 37 to 42, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.
-
44. Package comprising a pharmaceutical composition comprising a compound of formula I as defined in claim 1, or a pharmacologically acceptable salt or ester thereof, in combination with instructions to administer said composition with a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.
-
45. Package according to claim 44, wherein the dosing regimen is once daily.
-
46. Package according to claim 44, wherein the dosing regimen is once every other day.
-
47. Package according to any one of claims 44 to 46, wherein the central and peripheral nervous system associated disorder is a movement disorder, a gastrointestinal disturbance, an oedema formation state or hypertension.
-
48. Package as claimed in claim 47, wherein the movement disorder is restless leg syndrome, Parkinson'"'"'s disease or a pathological state involving Parkinsonism.
-
49. Package according to any one of claims 44 to 48, wherein the package further comprises a pharmaceutical composition comprising L-DOPA and/or an AADC.
-
50. Package according to any one of claims 44 to 49, wherein the compound of formula I is 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.
-
Specification